Activity at phencyclidine and mu opioid sites mediates the hyperalgesic and antinociceptive properties of the N-terminus of substance P in a model of visceral pain
暂无分享,去创建一个
[1] A. Larson,et al. Phencyclidine (PCP) receptors mediate substance P N-terminus-induced hyperalgesia while mu-type opioid receptors mediate its antinociceptive effect , 1994, Regulatory Peptides.
[2] A. Larson,et al. MK-801 and phencyclidine act at phencyclidine sites that are not linked to N-methyl-d-aspartate activity to inhibit behavioral sensitization to kainate , 1993, Neuroscience.
[3] A. Larson,et al. Modulation of kainic acid-induced activity in the mouse spinal cord by the amino terminus of substance P: sensitivity to opioid antagonists. , 1993, The Journal of pharmacology and experimental therapeutics.
[4] A. Larson,et al. DAMGO binding to mouse brain membranes: Influence of salts, guanine nucleotides, substance P, and substance P fragments , 1993, Peptides.
[5] A. Larson,et al. Amino terminus of substance P potentiates kainic acid-induced activity in the mouse spinal cord , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[6] R. Melzack,et al. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[7] D. Budai,et al. Modulation of N-methyl-D-aspartate and (R,S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) responses of spinal nociceptive neurons by a N-terminal fragment of substance P. , 1992, European journal of pharmacology.
[8] G. Gebhart,et al. Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex. , 1992, European journal of pharmacology.
[9] T. Yaksh,et al. Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists , 1992, Pain.
[10] K. McCarson,et al. Release of substance P into the superficial dorsal horn following nociceptive activation of the hindpaw of the rat , 1991, Brain Research.
[11] W. Willis,et al. Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined micro-iontophoretic application of n-methyl-d-aspartic acid and substance P , 1991, Pain.
[12] R. Melzack,et al. Central neural mediators of secondary hyperalgesia following heat injury in rats: Neuropeptides and excitatory amino acids , 1991, Neuroscience Letters.
[13] J. Stewart,et al. Effects of Substance P and SP(1‐7) on Dopamine Release from Rat Substantia Nigra , 1991, Annals of the New York Academy of Sciences.
[14] A. Hama,et al. MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy , 1991, Brain Research.
[15] Clifford J. Woolf,et al. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states , 1991, Pain.
[16] P. Contreras,et al. Contrasting Neurochemical Interactions of Tiletamine, a Potent Phencyclidine (PCP) Receptor Ligand, with the N‐Methyl‐D‐Aspartate‐Coupled and ‐Uncoupled PCP Recognition Sites , 1991, Journal of neurochemistry.
[17] O. Igwe,et al. Role of Substance P Amino Terminal Metabolites in Substance P-Induced Desensitization in Mice , 1990, Neuroscience.
[18] A. Larson,et al. Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[19] U. Ungerstedt,et al. The substance P(1–7) fragment is a potent modulator of substance P actions in the brain , 1990, Brain Research.
[20] H. Takagi,et al. Stimulus specificity of peripherally evoked substance P release from the rabbit dorsal horn in situ , 1989, Neuroscience.
[21] G. Pasternak,et al. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. , 1989, European journal of pharmacology.
[22] A. Larson,et al. Modulation of [3H]DAGO binding by substance P (SP) and SP fragments in the mouse brain and spinal cord via MU1 interactions , 1989, Neuropeptides.
[23] K. Franklin,et al. Techniques for Assessing the Effects of Drugs on Nociceptive Responses , 1989 .
[24] V. Seybold,et al. Phencyclidine and sigma receptors in rat spinal cord: Binding characterization and quantitative autoradiography , 1989, Synapse.
[25] R. Raffa,et al. Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse. , 1988, The Journal of pharmacology and experimental therapeutics.
[26] J. Henry,et al. N- and C-terminal fragments of substance P: spinal effects in the rat tail flick test , 1988, Brain Research Bulletin.
[27] P. Portoghese,et al. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist , 1988 .
[28] G. Wilcox,et al. Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists. , 1987, The Journal of pharmacology and experimental therapeutics.
[29] G. Urca,et al. IntrathecalN-methyl-d-aspartate (NMDA) activates both nociceptive and antinociceptive systems , 1987, Brain Research.
[30] I. Hendry,et al. Noxious heating of the skin releases immunoreactive substance P in the substantia gelatinosa of the cat: A study with antibody microprobes , 1987, Brain Research.
[31] G. Pasternak,et al. Naloxonazine actions in vivo. , 1986, European journal of pharmacology.
[32] J. Naranjo,et al. Antinociceptive and Met-enkephalin releasing effects of tachykinins and substance P fragments , 1986, Peptides.
[33] S. Sakurada,et al. Characterization of the hyperalgesic effect induced by intrathecal injection of substance P , 1985, Neuropharmacology.
[34] L. Terenius,et al. Measurement of Substance P Metabolites in Rat CNS , 1985, Journal of neurochemistry.
[35] S. Moochhala,et al. Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization , 1984, British journal of pharmacology.
[36] J. Stewart,et al. Substance P and behavior: Opposite effects of N-terminal and C-terminal fragments , 1983, Peptides.
[37] H. Kosterlitz,et al. Classification of opioid receptors. , 1983, British medical bulletin.
[38] G. Wilcox,et al. Intrathecal opioids block a spinal action of substance P in mice: Functional importance of both μ- and δ-receptors , 1982 .
[39] T. Hökfelt,et al. A fragment of substance P with specific central activity: SP(1–7) , 1982, Peptides.
[40] T. Fu,et al. Distribution of radioactivity in the spinal cord after intracerebroventricular and intravenous injection of radiolabeled opioid peptides in mice. , 1982, The Journal of pharmacology and experimental therapeutics.
[41] L. Iversen,et al. Purification and characterisation of a membrane-bound substance-P-degrading enzyme from human brain. , 1981, European journal of biochemistry.
[42] G. Wilcox,et al. Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.
[43] T. Jessell,et al. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo , 1980, Nature.
[44] R. Frederickson,et al. Dual actions of substance P on nociception: possible role of endogenous opioids , 1978 .
[45] E. B. Reeve,et al. Substance P and analgesia , 1976, Nature.